risvutatug rezetecan   Click here for help

GtoPdb Ligand ID: 14693

Synonyms: GSK'227 | GSK5764227 | HS-20093 | Ris-Rez
Compound class: Antibody
Comment: Risvutatug rezetecan (GSK5764227, formerly HS-20093; Ris-Rez) is an antibody-drug congugate that targets a camptothecin derived topoisomerase I inhibitor to (tumour) cells expressing CD276 (B7-H3) [2-3,5]. Peptide sequences for risvutatug's heavy and light chains are claimed in Hansoh patent US10899837B2, and these form the antibody named h1702 therein [4].
Click here for help
References
1. Duan J, Sun Y, Wang Q, Xing L, Wu L, Han L, Chen J, Liu B, Lu P, Shi H et al.. (2026)
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
Cancer Cell, 44 (4): 846-857.e3. [PMID:41791381]
2. Fabrizio FP, Muscarella LA, Rossi A. (2024)
B7-H3/CD276 and small-cell lung cancer: What's new?.
Transl Oncol, 39: 101801. [PMID:37865049]
3. Feustel K, Martin J, Falchook GS. (2024)
B7-H3 Inhibitors in Oncology Clinical Trials: A Review.
J Immunother Precis Oncol, 7 (1): 53-66. [PMID:38327753]
4. Gu J, Wang X, Ye X, Yang L, Zhang T, Tao W, Zhang L. (2021)
B7-H3 antibody, antigen-binding fragment thereof and medical use thereof.
Patent number: US10899837B2. Assignee: Hansoh Shanghai Healthtech Co Ltd, Changzhou Hansoh Pharmaceutical Co Ltd. Priority date: 30/03/2018. Publication date: 26/01/2021.
5. Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L et al.. (2026)
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.
Front Immunol, 17: 1907324. [PMID:42661867]